步长制药子公司撤回恩格列净片药品上市许可注册申请

Core Viewpoint - The company announced that its wholly-owned subsidiary, Shandong Danhong Pharmaceutical Co., Ltd., received a termination notice from the National Medical Products Administration regarding the drug registration application for "Empagliflozin Tablets," which is used for the treatment of type 2 diabetes. The withdrawal of this application will not have a significant impact on the company's current performance [1]. Group 1 - The drug "Empagliflozin Tablets" is intended for the treatment of type 2 diabetes [1]. - The application for the drug's market approval has been officially withdrawn [1]. - The withdrawal of the application is not expected to significantly affect the company's current financial results [1].